Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Drops By 69.9%

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a significant drop in short interest in July. As of July 15th, there was short interest totaling 27,481 shares, a drop of 69.9% from the June 30th total of 91,267 shares. Based on an average daily trading volume, of 29,455 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.8% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings cut Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Pulmatrix

A hedge fund recently bought a new position in Pulmatrix stock. Dimensional Fund Advisors LP bought a new stake in Pulmatrix, Inc. (NASDAQ:PULM) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned 0.30% of Pulmatrix as of its most recent SEC filing. Institutional investors own 11.84% of the company’s stock.

Pulmatrix Trading Up 4.8%

Pulmatrix stock traded up $0.08 during midday trading on Monday, hitting $1.73. 9,128 shares of the stock were exchanged, compared to its average volume of 45,841. The stock’s 50-day simple moving average is $1.52 and its 200 day simple moving average is $1.84. Pulmatrix has a fifty-two week low of $1.16 and a fifty-two week high of $5.80. The stock has a market capitalization of $6.32 million, a price-to-earnings ratio of -1.41 and a beta of 1.90.

Pulmatrix (NASDAQ:PULM) last posted its earnings results on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share for the quarter.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).